Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgical Closure vs Anti-TNF for Perianal Fistulas in Crohn's Disease
NCT06441526Phase 3Completed
- Sponsor
- University of Amsterdam
- Start
- Sep 2013
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of infliximab and adalimumab in perianal fistula and Crohn's disease (2 arms), sponsored by University of Amsterdam. Primary endpoint: Radiological fistula healing at MRI at 18 months. Started Sep 2013; status: completed.
02
Drugs
infliximabadalimumab
03
Conditions
perianal fistulaCrohn's disease
Beyond the preview
Go deeper on NCT06441526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441526.